Dr. Suresh Muthukumaraswamy, an associate professor of psychopharmacology at the University of Auckland, dives deep into the world of psychedelics and mental health. He compares the psychedelic effects of LSD with ketamine’s rapid antidepressant benefits, illuminating the promising role of scopolamine too. The conversation unpacks the complexities of placebo effects and emphasizes the urgent need for more research into psychedelics as therapeutic options. Suresh also discusses the evolving regulatory landscape and the societal challenges ahead in this groundbreaking field.

Dr. Suresh Muthukumaraswamy, lead researcher in the world's first LSD microdosing clinical trial, discusses the unique design of his experiment, challenges faced, and potential benefits. They explore therapy in psychedelic assisted psychotherapy, regulatory considerations, and the relationship between the Maori and plant medicines in New Zealand.